Investigation of Supra Fiber in the Treatment of Adults With Constipation
Launched by AUGUSTA UNIVERSITY · Feb 1, 2011
Trial Information
Current as of July 01, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Constipation as defined by Rome III criteria (3,4). Also, patients should have insufficient criteria for IBS, and only rarely experience loose stools without the use of laxatives.
- • Adults between the ages of 18-75 years
- Exclusion Criteria:
- • Patients taking drugs that are known to be constipating will be excluded or asked to discontinue medications for at least 2 weeks and reassessed. Patients who remain constipated will be eligible for enrollment.
- • Co-morbid illnesses such as severe cardiovascular disease, chronic renal failure
- • Previous gastrointestinal surgery except cholecystectomy and appendectomy.
- • Neurologic diseases such as multiple sclerosis, strokes, spinal cord injuries, and those who have problems with cognizance, i.e. a mini-mental score of \<15 and/or are legally blind
- • Hirschsprung' s disease, or active local anorectal problems such as anal fissures, bleeding hemorrhoids,
- • Alternating constipation and diarrhea and those who fulfill the Rome-III criteria for irritable bowel syndrome.
- • Subjects with a known allergy to psyllium or plums.
About Augusta University
Augusta University is a prominent academic institution dedicated to advancing healthcare through innovative research and clinical trials. As a leader in medical education and patient care, Augusta University conducts rigorous clinical studies aimed at improving treatment outcomes and enhancing patient quality of life. The university’s commitment to interdisciplinary collaboration fosters a dynamic research environment, enabling the exploration of novel therapies and interventions across a wide range of medical fields. With a focus on ethical standards and patient safety, Augusta University strives to translate scientific discoveries into tangible benefits for the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Iowa City, Iowa, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials